BioPharma Shuffle: Amgen's Secret Overhaul and CRISPR's Next Big Catalyst
Global Report·- US biopharmaceutical and medical device companies are accelerating core pipelines and experiencing leadership changes ahead of the 2026 commercialization window. - Amgen restructured to focus resources, Regeneron faced legal pressure alongside an FDA approval, CRISPR Therapeutics gained attention from expanded indications, Sarepta appointed a new CEO, and Iovance reported strong Q2 earnings driven by its TIL therapy. - Zai Lab achieved positive 3 phase trial results while Novavax suffered revenue declines due to the revocation of its old COVID-19 vaccine emergency use authorization.Top 10 US Stock Losers (8.21)
Top Gainers&Losers·- The article reports the performance of major US stock indices and lists the top declining stocks on August 21. - Seabridge Gold fell 9.35% with a trading volume of 92,784,000 dollars, while Hut 8 Mining dropped 8.79% with a trading volume of 790,000,000 dollars. - Alibaba decreased by 8.57% with a trading volume of 3,930,000,000 dollars, bringing its year-to-date decline to 17.8%.